Early graft loss ‐ not reported · live donor nephrectomy (primary outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Delayed graft function ‐ not reported · live donor nephrectomy (primary outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute rejection ‐ not reported · live donor nephrectomy (primary outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ureteric complications ‐ not reported · live donor nephrectomy (primary outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Kidney function · live donor nephrectomy (primary outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft loss · live donor nephrectomy (primary outcomes)
Summary of findings table ‐ Laparoscopic showed no clear difference in one‐year graft loss compared with hand‐assisted (low certainty).
1 finding from 1 review
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
Risk of receiving any allogeneic blood product (data only available for intraoperative blood product use) · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of receiving any allogeneic blood product (data only available… compared with placebo (very low certainty).
1 finding from 1 review
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).
1 finding from 1 review
Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery
Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).
1 finding from 1 review
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality · people with AAA
It is very uncertain whether retroperitoneal approach changes mortality compared with transperitoneal approach (very low certainty).
1 finding from 1 review
Complications: hematoma · people with AAA
It is very uncertain whether retroperitoneal approach changes complications: hematoma compared with transperitoneal approach (very low certainty).
1 finding from 1 review
Complications: abdominal wall hernia · people with AAA
It is very uncertain whether retroperitoneal approach changes complications: abdominal wall hernia compared with transperitoneal approach (very low certainty).
1 finding from 1 review
Complications: chronic wound pain · people with AAA
It is very uncertain whether retroperitoneal approach changes complications: chronic wound pain compared with transperitoneal approach (very low certainty).
1 finding from 1 review